查看購物車
  • Simplified Chinese
  • English
  • Japanese
歐洲球囊主動脈瓣成形術市場預測（至 2031 年）- 區域分析 - 依產品類型（非順應性球囊和半順應性球囊）
市場調查報告書
商品編碼
1765034

歐洲球囊主動脈瓣成形術市場預測（至 2031 年）- 區域分析 - 依產品類型（非順應性球囊和半順應性球囊）

Europe Balloon Aortic Valvuloplasty Market Forecast to 2031 - Regional Analysis - by Product Type (Non Compliant Balloons and Semi Compliant Balloons)
出版日期: | 出版商: The Insight Partners | 英文 81 Pages | 訂單完成後即時交付

價格

2023 年歐洲球囊主動脈瓣成形術市場價值為 5,034 萬美元，預計到 2031 年將達到 7,467 萬美元；預計 2023 年至 2031 年的複合年成長率為 5.1%。

TAVI 技術的改進與研發結合，推動歐洲球囊主動脈瓣成形術市場發展

經導管主動脈瓣置換術（TAVR）最初僅用於無法手術或風險極高的嚴重主動脈瓣狹窄患者。然而，隨著瓣膜技術的不斷發展和隨機試驗的結果，其應用範圍已擴大到更年輕、風險更低的患者，並使其成為主動脈瓣疾病的主流治療方法。隨著瓣膜生產技術的進步，生物瓣膜越來越受到年輕、風險較低患者的青睞。由於其微創特性，大多數瓣膜置換手術很快將透過TAVR進行。新一代經導管心臟瓣膜顯著提高了手術效果、安全性和患者預後，使TAVR成為不同風險族群的理想選擇。

預測心臟瓣膜植入後的表現對於 TAVR 的成功至關重要。為了確保瓣膜功能正常，並最大程度地減少植入後併發症，最好在植入前對選定的心臟瓣膜進行機械評估。將工程分析應用於心臟瓣膜機械評估的一個潛在且有效的解決方案是結合基於深度學習 (DL) 的系統，以推進和簡化與 TAVR 相關的計算生物力學分析。近年來，深度學習技術的巨大發展已使許多電腦視覺任務（包括影像分類、影像分割和目標檢測）的表現達到最高水準。深度學習已廣泛應用於各種心臟影像應用，包括診斷、預後、風險分層以及治療/外科治療計劃。許多研究已經探討了使用深度學習方法評估 TAVR 結果以預測術後併發症和人工瓣膜缺陷。

透過不斷研發，TAVR 未來充滿突破性的可能性，進一步鞏固其作為心血管醫學變革療法的地位。目前，只有 Edwards SAPIEN 3 Ultra、Medtronic EVOLUT FX 和 Abbott Navitor 瓣膜獲得了 FDA 的批准。雖然 TAVR 的大部分臨床經驗都與 Edwards 和 Medtronic 瓣膜系統有關，但潛在的經導管心臟瓣膜陣容不僅限於這些領先者，還有多達五到十種新的 TAVR 瓣膜處於開發階段。第四種經導管心臟瓣膜，即波士頓科學 Acurate-neo2 瓣膜，於 2020 年在歐洲獲得批准；在某些地方，它已經對 1,500 名不同風險等級的患者完成了隨機臨床試驗。第五種瓣膜 JenaValve（JenaValve 技術），已在歐盟獲得批准，並擁有 FDA 的先進設備稱號和研究設備豁免；然而，這種瓣膜主要針對純主動脈瓣關閉不全患者進行開發。

除了對現有瓣膜進行改進外，全球各地的公司還在開發多種瓣膜，預計這些瓣膜將在未來幾年提高輸送能力、耐用性和臨床療效。 TAVR 的前景一片光明，適應症不斷增加，手術量激增，提供該手術的臨床中心也越來越多，但長期耐用性仍然是一個關鍵問題。目前可用的瓣膜瓣葉取自豬或牛心包組織。為了提高長期耐用性，正在開發結合創新瓣葉材料和其他設計創新的新型瓣膜平台。一些新的試驗有望為尋求長期解決方案的 TAVR 手術人員提供重要指導。 SMART（即隨機化小瓣環 Evolut 或 SAPIEN 試驗）是第一個由業界（美敦力）贊助的隨機化頭對頭比較試驗，比較兩種最常用的 TAVR 設備：SAPIEN 3 和 Evolut 在小解剖結構中的應用。該試驗在北美、歐洲、中東和非洲的 83 個國際地點進行。試驗招募了 716 名主動脈環較小（根據多偵測器電腦斷層掃描，主動脈環面積為 430 平方毫米或更小）且有症狀的重度先天性主動脈瓣狹窄的參與者。 2024 年 4 月，美國心臟學會宣布 SMART 試驗的結果表明，與接受 SAPIEN 3 瓣膜 TAVR 的患者相比，接受 Evolut 瓣膜 TAVR 的小主動脈環患者在一年後具有相似的臨床結果和更優異的瓣膜性能。研究人員表示，就兩種瓣膜類型的臨床結果而言，結果均令人鼓舞。他們指出，進一步的試驗有助於闡明 TAVR 是否具有隨時間持續的早期優勢，以及哪種現有和即將推出的經導管心臟瓣膜能提供最佳效果。研究人員將在未來五年內繼續追蹤結果。因此，專注於改進 TAVI 程序的研究和開發活動可能會為球囊主動脈瓣成形術市場帶來新的趨勢。

歐洲球囊主動脈瓣成形術市場概況

歐洲球囊主動脈瓣成形術市場的成長與瓣膜疾病盛行率的上升以及人們對微創手術日益成長的偏好有關。心血管疾病持續成長，仍是德國的主要死亡原因之一。心臟瓣膜疾病的發生率隨著年齡的成長而急劇上升。主動脈瓣狹窄是一種常見的心臟瓣膜疾病，如果不治療，預後不佳。在這種情況下，建議採用經導管主動脈瓣瓣膜植入術 (TAVI) 或經導管主動脈瓣置換術 (SAVR)。 TAVI 是德國主動脈瓣狹窄的標準治療方法。

根據2023年發表的一項題為《德國經導管主動脈瓣植入的醫療保健服務》的研究，2021年共實施了26,506例TAVI手術。與2021年相比，預計2035年TAVI手術將增加4,673例。此外，基於德國胸腔心臟血管外科協會（GSTCVS）於1980年建立的長期自願登記系統，分析了2022年德國78個心臟外科部門實施的所有胸腔外科、心臟外科和血管外科手術的明確資料。 2022年共實施了93,913例心臟外科手術。其中，實施了38,492例心臟瓣膜手術，包括14,852例單瓣心臟瓣膜手術、2,880例雙瓣心臟瓣膜手術和296例三瓣心臟瓣膜手術。此外，也進行了約20,272例經導管心臟瓣膜手術。重點關注2022年主動脈瓣膜手術的分佈，向登記處報告了17,818例TAVI和7,798例SAVR。

FRANCE-TAVI 登記系統於 2022 年發布了一份關於法國隊列中 TAVR 趨勢和演變的最新報告。約有 85,000 名患者入組，平均年齡為 83 歲。手術數量從 2010 年的 1,556 例增加到 2021 年的 14,114 例。此外，TAVR 的使用主要局限於高風險族群，在法國年輕患者中仍然不常見。根據 2023 年發布的《法國經導管主動脈瓣置換術使用與年齡和性別的關係》報告，共有 107,397 名患者接受了單獨主動脈瓣置換術（59.1% 為 TAVR，40.9% 為 SAVR）。在65歲及以上患者中，從2015年到2020年，TAVR的比例增加了63.2％。隨著人口老化的加劇，心臟瓣膜疾病的盛行率預計將激增。

由於瓣膜疾病患者人數不斷增加，以及老年人口（老年人更容易患瓣膜疾病）的不斷增加，英國球囊主動脈瓣成形術市場可能會持續成長。根據英國註冊慈善機構 Age UK 2020 年發布的一項研究，英國 65 歲及以上人口接近 1,200 萬人。預計到 2030 年，英國百歲老人的數量將達到或超過 2.1 萬，五分之一的人口將達到 65 歲及以上。根據 2021 年發表在開放取用期刊《Open Heart》上的一項題為《揭示英國重度主動脈瓣狹窄的可治療負擔》的研究，英國約有 30 萬人患有主動脈瓣狹窄，這是一種可能致命的心臟病。在主動脈瓣狹窄患者中，約有 19.9 萬人（68%）患有重度主動脈瓣狹窄。 2024年，172,859名患有嚴重主動脈瓣狹窄的患者死亡。隨著人口老化，英國人口對主動脈瓣狹窄治療的需求也增加。此外，根據《歐洲心臟雜誌》的數據，2015年英國約有150萬65歲以上人士患有心臟瓣膜疾病，包括主動脈瓣狹窄。預計到2046年，這一數字將加倍，到2056年將達到330萬，這可以歸因於人口老化。

法國政府機構為提高公眾對瓣膜置換手術的認知而採取的舉措，促進了市場成長。歐洲經皮心血管介入協會 (ECI) 發起了「生命瓣膜」(Valve for Life) 計劃，旨在彌補歐洲心臟瓣膜疾病護理的缺口。該計劃始於2015年，旨在彌補心臟瓣膜護理方面的資訊缺口，提高公眾對心臟瓣膜疾病的認知，並促進更廣泛地獲得導管瓣膜介入治療。其目標是透過動員醫生、政策制定者和醫療機構參與，鼓勵實施挽救生命的手術，到2020年將嚴重心臟瓣膜疾病的治療率提高20%。該計畫已在法國、波蘭和葡萄牙試行，並顯著提高了患者接受的挽救生命的干涉措施的數量。

為了提高人們對心臟瓣膜疾病的認知，各組織正致力於提高公眾意識並資助相關研究計畫。 「心臟瓣膜之聲」是英國致力於心臟瓣膜疾病的慈善機構。它與患者和臨床醫生合作，致力於提高人們對心臟瓣膜疾病的認知，並改善診斷和治療。它匯集了一群擁有真實心臟瓣膜疾病經驗的人士，包括該領域的多學科專家團隊（心臟病專家和心臟外科醫生）、心臟病患者協會以及患者。此外，英國心臟基金會也籌集資金，用於研究心臟和循環系統疾病（包括心臟瓣膜疾病）的治療方法。

歐洲球囊主動脈瓣成形術市場收入及預測（2031 年）（百萬美元）

歐洲球囊主動脈瓣成形術市場細分

歐洲球囊主動脈瓣成形術市場依產品類型和國家分類。

根據產品類型，歐洲球囊主動脈瓣成形術市場細分為非順應性球囊和半順應性球囊。非順應性球囊在2023年佔據了較大的市佔率。

依國家/地區分類，歐洲球囊主動脈瓣成形術市場分為德國、英國、法國、義大利、西班牙和歐洲其他地區。 2023年，德國佔據了歐洲球囊主動脈瓣成形術市場佔有率的主導地位。

B Braun SE；TT Medical, Inc.；Balton；Becton Dickinson and Co；Edwards Lifesciences Corp；Balt；杭州啟蒙醫療科技有限公司；以及 OSYPKA 是歐洲球囊主動脈瓣成形術市場的一些領先公司。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解

第3章：研究方法

  • 二次研究
  • 初步研究
    • 假設表述：
    • 宏觀經濟因素分析：
    • 顯影基數：
    • 數據三角測量：
    • 國家級資料：

第4章：歐洲球囊主動脈瓣成形術市場格局

  • 概述
  • 2023 年各產品類型區域定價分析

第5章：歐洲球囊主動脈瓣成形術市場-關鍵市場動態

  • 市場促進因素
    • 主動脈瓣狹窄盛行率上升
    • 微創手術需求不斷成長
  • 市場限制
    • 手術費用高昂
  • 市場機會
    • 主動脈瓣置換技術的進展
  • 未來趨勢
    • TAVI 的改進與研發結合
  • 促進因素和限制因素的影響：

第6章：球囊主動脈瓣成形術市場 - 歐洲市場分析

  • 2021-2031年歐洲氣球主動脈瓣成形術市場收入
  • 2023年市場定位分析

第7章：歐洲球囊主動脈瓣成形術市場分析－依產品類型

  • 概述
  • 歐洲球囊主動脈瓣成形術市場—收入與預測分析—依產品類型
  • 歐洲球囊主動脈瓣成形術市場--產量與預測分析-依產品類型
  • 不合規氣球
  • 半順應性氣球

第8章：歐洲球囊主動脈瓣成形術市場-國家分析

  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其餘

第9章：公司簡介

  • B Braun SE
  • TT Medical, Inc.
  • Balton
  • Becton Dickinson and Co
  • Edwards Lifesciences Corp
  • Balt
  • Venus MedTech HangZhou Inc
  • OSYPKA

第 10 章：附錄

Product Code: BMIRE00031480

The Europe balloon aortic valvuloplasty market was valued at US$ 50.34 million in 2023 and is expected to reach US$ 74.67 million by 2031; it is estimated to register a CAGR of 5.1% from 2023 to 2031.

Improvements in TAVI Combined with Research and Development Fuel Europe Balloon Aortic Valvuloplasty Market

TAVR was originally considered only for patients with severe aortic stenosis who were considered inoperable or at very high risk. However, continuous technological evolution in valve technology and the results of randomized trials have expanded its usage to younger and lower-risk patients, making it a mainstream treatment for aortic valve disease. With developments in valve production technologies, bioprosthetic heart valves are becoming more popular and applicable to younger and lower-risk patients. With its minimally invasive feature, a majority of valve replacements will soon be via TAVR. New-generation transcatheter heart valves have substantially improved procedural efficacy, safety, and patient outcomes, making TAVR an appealing option for different patient risk groups.

Predicting the performance of the heart valve upon implantation is critically important for a successful TAVR. It is desirable to mechanically assess selected heart valves before implantation to ensure proper valve function with minimal complications after implantation. A potential practical and effective solution for applying engineering analysis to the mechanical assessment of heart valves is incorporating deep learning (DL)-based systems to advance and simplify the computational biomechanical analyses relevant to TAVR. In recent years, immense developments in DL techniques have led to state-of-the-art performances in many computer vision tasks, including image classification, image segmentation, and object detection. DL has been extensively investigated for various cardiac imaging applications, including diagnostic, prognostic, risk stratification, and therapeutic/surgical treatment planning. Numerous studies have investigated DL approaches for assessing TAVR outcomes to predict postoperative complications and prosthetic valve defects.

Through continuous research and development, the future of TAVR promises breakthrough possibilities, further strengthening its place as a transformative therapy in cardiovascular medicine. Currently, only the Edwards SAPIEN 3 Ultra, Medtronic EVOLUT FX, and Abbott Navitor valves have been approved by the FDA. Although most of the clinical experience with TAVR is linked to the Edwards and Medtronic valve systems, the potential transcatheter heart valves lineup extends beyond these leaders, with as many as five to ten new TAVR valves in the development phase. A fourth transcatheter heart valve, the Boston Scientific Acurate-neo2 valve, was approved in 2020 in Europe; in a few places, it has accomplished its randomized clinical testing with 1,500 patients across all levels of risk. A fifth valve, the JenaValve (JenaValve Technology), is approved in the EU and has an advance-device designation and an investigational device exemption from the FDA; however, this valve is being developed mainly for patients with pure aortic regurgitation.

In addition to modifications to the valves that are already available, several valves are under development by companies worldwide, and these are expected to enhance deliverability, durability, and clinical outcomes in the years to come. The future of TAVR appears bright, with indications growing, procedural volumes soaring, and an increasing number of clinical sites offering the procedure, although long-term durability remains a key concern. The leaflets of currently available valves are derived from porcine or bovine pericardial tissue. New valve platforms incorporating creative leaflet materials and other design innovations are being developed to increase long-term durability. Some new trials promise to offer crucial guidance for TAVR operators seeking to offer long-term solutions. The SMART (i.e., Small Annuli Randomized to Evolut or SAPIEN) trial is the first randomized industry-sponsored (Medtronic) head-to-head comparison of the two most commonly used TAVR devices: SAPIEN 3 and Evolut in small anatomies. The trial was conducted at 83 international sites in North America, Europe, and the Middle East & Africa. The trial enrolled 716 participants with a small aortic annulus (aortic annulus area of 430 mm2 or less based on multi-detector computed tomography) and symptomatic severe native aortic stenosis. In April 2024, the American College of Cardiology announced that findings from the SMART trial demonstrated that patients with a small aortic annulus who underwent TAVR with Evolut valve had similar clinical outcomes and superior valve performance at one year compared with patients who underwent TAVR with SAPIEN 3 valve. Researchers said the results are encouraging in terms of the clinical outcomes of both valve types. They noted that further trials could help shed light on whether TAVR offers an early advantage that is sustained with time and which of the current and upcoming transcatheter heart valves offer the best results. Researchers will continue to track outcomes over the next five years. Thus, the research and development activities focused on improving TAVI procedures are likely to bring in new trends in the balloon aortic valvuloplasty market.

Europe Balloon Aortic Valvuloplasty Market Overview

The Europe balloon aortic valvuloplasty market growth is associated with the rising prevalence of valvular diseases and the growing preference for minimally invasive surgeries. Cardiovascular diseases continue to increase and are still among the leading causes of death in Germany. The incidence of heart valve disease progresses immensely with age. Aortic stenosis is a common valvular heart disease with a dismal prognosis when untreated. TAVI or SAVR is recommended in such conditions. TAVI is a standard treatment for aortic valve stenosis in the country.

As per a study titled "Healthcare provision of transcatheter aortic valve implantation in Germany," published in 2023, a total of 26,506 TAVI procedures were performed in 2021. Compared to 2021, an increase of 4,673 TAVI procedures is to be expected by 2035. Moreover, based on a longtime voluntary registry founded by the German Society for Thoracic and Cardiovascular Surgery (GSTCVS) in 1980, well-defined data of all thoracic, cardiac, and vascular surgical procedures performed in 78 German heart surgery departments during 2022 were analyzed. A total of 93,913 heart surgical procedures were performed in 2022. Of these, 38,492 heart valve procedures were performed, including 14,852 isolated heart valve procedures performed as single, 2,880 as double, and 296 as triple valve procedures. In addition, about 20,272 transcatheter heart valve procedures were carried out. Focusing on the distribution of aortic valve procedures for 2022, 17,818 TAVI and 7,798 SAVRs were reported to the registry.

The FRANCE-TAVI Registry published an updated report of trends and evolution of TAVR in the French cohort in 2022. About 85,000 patients were enrolled, with an average age of 83 years. The number of procedures increased from 1,556 in 2010 to 14,114 in 2021. In addition, the use of TAVR was mainly restricted to those at high risk and remained uncommon in young patients in the country. According to the "Association of Age and Sex with Use of Transcatheter Aortic Valve Replacement in France," published in 2023, a total of 107,397 patients underwent an isolated aortic valve replacement (59.1% TAVR, 40.9% SAVR). In patients aged 65 years and above, the proportion of TAVR increased by 63.2% from 2015 to 2020. With a rising aging population, the prevalence of valvular heart disease is projected to surge.

The balloon aortic valvuloplasty market in the UK is likely to grow due to the rising number of people suffering from valvular diseases and the increasing geriatric population who are more susceptible to valvular diseases. According to a study published by Age UK-a registered charity in the UK-in 2020, there were nearly 12 million people aged 65 and above in the UK. It is estimated that the number of centenarians living in the UK will be 21,000 or more, and one in five people will be aged 65 and above by 2030. As per the research study titled "Uncovering the treatable burden of severe aortic stenosis in the UK," published in 2021 in the open-access journal Open Heart, ~300,000 people have aortic valve stenosis, a potentially deadly heart condition in the UK. Of the people with aortic stenosis, ~199,000 (68%) had severe aortic stenosis disease. 172,859 of these patients with severe aortic stenosis succumbed to death in 2024. The UK population's need for treatment of aortic stenosis rises as the population ages. Moreover, according to the European Heart Journal, about 1.5 million people in the UK aged 65 or over suffered from heart valve disease, including aortic stenosis, in 2015. The number is projected to double by 2046 and reach 3.3 million by 2056, which can be attributed to the aging population.

Initiatives undertaken by French government organizations to enhance awareness regarding valve replacement surgeries support market growth. The European Association of Percutaneous Cardiovascular Interventions launched the Valve for Life initiative to address the gap in heart valve disease care in Europe. It started in 2015 with the intention of addressing information gaps in heart valve care, increasing public awareness of heart valve disease, and facilitating better access to catheter-based valve interventions. The goal was to achieve a 20% improvement in the treatment of severe heart valve disease in 2020 by involving doctors, policymakers, and healthcare authorities to encourage the implementation of life-saving procedures. The program was trialed in France, Poland, and Portugal, where it led to a measurable increase in life-saving interventions for patients.

In order to raise understanding of heart valvular disease, various organizations are working toward making people more aware and funding research projects. Heart Valve Voice is a UK-dedicated heart valve disease charity. It works with patients and clinicians to improve people's awareness regarding heart valve disease and enhance diagnosis and treatment. It is a collection of people with real experiences of heart valve disease, including a multi-disciplinary group of experts in the field (cardiologists and cardiac surgeons), cardiac patient societies, and patients. Additionally, the British Heart Foundation raises funds to research cures and treatments for heart and circulatory diseases, including heart valve disease.

Europe Balloon Aortic Valvuloplasty Market Revenue and Forecast to 2031 (US$ Million)

Europe Balloon Aortic Valvuloplasty Market Segmentation

The Europe balloon aortic valvuloplasty market is categorized into product type and country.

Based on product type, the Europe balloon aortic valvuloplasty market is segmented into non compliant balloons and semi compliant balloons. The non compliant balloons segment held a larger market share in 2023.

By country, the Europe balloon aortic valvuloplasty market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe balloon aortic valvuloplasty market share in 2023.

B Braun SE; TT Medical, Inc.; Balton; Becton Dickinson and Co; Edwards Lifesciences Corp; Balt; Venus MedTech HangZhou Inc; and OSYPKA are some of the leading companies operating in the Europe balloon aortic valvuloplasty market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Europe Balloon Aortic Valvuloplasty Market Landscape

  • 4.1 Overview
  • 4.2 Regional Pricing Analysis, By Product Type, 2023

5. Europe Balloon Aortic Valvuloplasty Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Prevalence of Aortic Valve Stenosis
    • 5.1.2 Increasing Demand for Minimally Invasive Procedures
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Procedures
  • 5.3 Market Opportunities
    • 5.3.1 Advancements in Aortic Valve Replacement Technologies
  • 5.4 Future Trends
    • 5.4.1 Improvements in TAVI Combined with Research and Development
  • 5.5 Impact of Drivers and Restraints:

6. Balloon Aortic Valvuloplasty Market - Europe Market Analysis

  • 6.1 Europe Balloon Aortic Valvuloplasty Market Revenue (US$ Thousand), 2021-2031
  • 6.2 Market Positioning Analysis, 2023

7. Europe Balloon Aortic Valvuloplasty Market Analysis - by Product Type

  • 7.1 Overview
  • 7.2 Europe Balloon Aortic Valvuloplasty Market - - Revenue and Forecast Analysis - by Product Type
  • 7.3 Europe Balloon Aortic Valvuloplasty Market - - Volume and Forecast Analysis - by Product Type
  • 7.4 Non Compliant Balloons
    • 7.4.1 Overview
    • 7.4.2 Non Compliant Balloons: Europe Balloon Aortic Valvuloplasty Market - Revenue and Forecast to 2031 (US$ Thousand)
  • 7.5 Semi Compliant Balloons
    • 7.5.1 Overview
    • 7.5.2 Semi Compliant Balloons: Europe Balloon Aortic Valvuloplasty Market - Revenue and Forecast to 2031 (US$ Thousand)

8. Europe Balloon Aortic Valvuloplasty Market - Country Analysis

  • 8.1 Europe
    • 8.1.1 Europe Balloon Aortic Valvuloplasty Market Overview
    • 8.1.2 Europe Balloon Aortic Valvuloplasty Market - Revenue and Forecast Analysis - by Country
      • 8.1.2.1 Germany: Europe Balloon Aortic Valvuloplasty Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 8.1.2.1.1 Germany: Europe Balloon Aortic Valvuloplasty Market Breakdown, by Product Type
        • 8.1.2.1.2 Germany: Europe Balloon Aortic Valvuloplasty Market - Volume and Forecast Analysis (Units) - by Product Type
      • 8.1.2.2 United Kingdom: Europe Balloon Aortic Valvuloplasty Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 8.1.2.2.1 United Kingdom: Europe Balloon Aortic Valvuloplasty Market Breakdown, by Product Type
        • 8.1.2.2.2 United Kingdom: Europe Balloon Aortic Valvuloplasty Market - Volume and Forecast Analysis (Units) - by Product Type
      • 8.1.2.3 France: Europe Balloon Aortic Valvuloplasty Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 8.1.2.3.1 France: Europe Balloon Aortic Valvuloplasty Market Breakdown, by Product Type
        • 8.1.2.3.2 France: Europe Balloon Aortic Valvuloplasty Market - Volume and Forecast Analysis (Units) - by Product Type
      • 8.1.2.4 Italy: Europe Balloon Aortic Valvuloplasty Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 8.1.2.4.1 Italy: Europe Balloon Aortic Valvuloplasty Market Breakdown, by Product Type
        • 8.1.2.4.2 Italy: Europe Balloon Aortic Valvuloplasty Market - Volume and Forecast Analysis (Units) - by Product Type
      • 8.1.2.5 Spain: Europe Balloon Aortic Valvuloplasty Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 8.1.2.5.1 Spain: Europe Balloon Aortic Valvuloplasty Market Breakdown, by Product Type
        • 8.1.2.5.2 Spain: Europe Balloon Aortic Valvuloplasty Market - Volume and Forecast Analysis (Units) - by Product Type
      • 8.1.2.6 Rest of Europe Balloon Aortic Valvuloplasty Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 8.1.2.6.1 Rest of Europe Balloon Aortic Valvuloplasty Market Breakdown, by Product Type
        • 8.1.2.6.2 Rest of Europe Balloon Aortic Valvuloplasty Market - Volume and Forecast Analysis (Units) - by Product Type

9. Company Profiles

  • 9.1 B Braun SE
    • 9.1.1 Key Facts
    • 9.1.2 Business Description
    • 9.1.3 Products and Services
    • 9.1.4 Financial Overview
    • 9.1.5 SWOT Analysis
    • 9.1.6 Key Developments
  • 9.2 TT Medical, Inc.
    • 9.2.1 Key Facts
    • 9.2.2 Business Description
    • 9.2.3 Products and Services
    • 9.2.4 Financial Overview
    • 9.2.5 SWOT Analysis
    • 9.2.6 Key Developments
  • 9.3 Balton
    • 9.3.1 Key Facts
    • 9.3.2 Business Description
    • 9.3.3 Products and Services
    • 9.3.4 Financial Overview
    • 9.3.5 SWOT Analysis
    • 9.3.6 Key Developments
  • 9.4 Becton Dickinson and Co
    • 9.4.1 Key Facts
    • 9.4.2 Business Description
    • 9.4.3 Products and Services
    • 9.4.4 Financial Overview
    • 9.4.5 SWOT Analysis
    • 9.4.6 Key Developments
  • 9.5 Edwards Lifesciences Corp
    • 9.5.1 Key Facts
    • 9.5.2 Business Description
    • 9.5.3 Products and Services
    • 9.5.4 Financial Overview
    • 9.5.5 SWOT Analysis
    • 9.5.6 Key Developments
  • 9.6 Balt
    • 9.6.1 Key Facts
    • 9.6.2 Business Description
    • 9.6.3 Products and Services
    • 9.6.4 Financial Overview
    • 9.6.5 SWOT Analysis
    • 9.6.6 Key Developments
  • 9.7 Venus MedTech HangZhou Inc
    • 9.7.1 Key Facts
    • 9.7.2 Business Description
    • 9.7.3 Products and Services
    • 9.7.4 Financial Overview
    • 9.7.5 SWOT Analysis
    • 9.7.6 Key Developments
  • 9.8 OSYPKA
    • 9.8.1 Key Facts
    • 9.8.2 Business Description
    • 9.8.3 Products and Services
    • 9.8.4 Financial Overview
    • 9.8.5 SWOT Analysis
    • 9.8.6 Key Developments

10. Appendix

  • 10.1 About The Insight Partners

List Of Tables

  • Table 1. Europe Balloon Aortic Valvuloplasty Market Segmentation
  • Table 2. Regional Pricing Analysis, By Product Type, 2023
  • Table 3. Europe Balloon Aortic Valvuloplasty Market - Revenue and Forecast to 2031 (US$ Thousand) - by Product Type
  • Table 4. Europe Balloon Aortic Valvuloplasty Market - Volume (Units) and Forecast to 2031(Units) - by Product Type
  • Table 5. Germany: Europe Balloon Aortic Valvuloplasty Market - Revenue and Forecast to 2031(US$ Thousand) - by Product Type
  • Table 6. Germany: Europe Balloon Aortic Valvuloplasty Market - Volume and Forecast to 2031 (Units) - by Product Type
  • Table 7. United Kingdom: Europe Balloon Aortic Valvuloplasty Market - Revenue and Forecast to 2031(US$ Thousand) - by Product Type
  • Table 8. United Kingdom: Europe Balloon Aortic Valvuloplasty Market - Volume and Forecast to 2031 (Units) - by Product Type
  • Table 9. France: Europe Balloon Aortic Valvuloplasty Market - Revenue and Forecast to 2031(US$ Thousand) - by Product Type
  • Table 10. France: Europe Balloon Aortic Valvuloplasty Market - Volume and Forecast to 2031 (Units) - by Product Type
  • Table 11. Italy: Europe Balloon Aortic Valvuloplasty Market - Revenue and Forecast to 2031(US$ Thousand) - by Product Type
  • Table 12. Italy: Europe Balloon Aortic Valvuloplasty Market - Volume and Forecast to 2031 (Units) - by Product Type
  • Table 13. Spain: Europe Balloon Aortic Valvuloplasty Market - Revenue and Forecast to 2031(US$ Thousand) - by Product Type
  • Table 14. Spain: Europe Balloon Aortic Valvuloplasty Market - Volume and Forecast to 2031 (Units) - by Product Type
  • Table 15. Rest of Europe Balloon Aortic Valvuloplasty Market - Revenue and Forecast to 2031(US$ Thousand) - by Product Type
  • Table 16. Rest of Europe Balloon Aortic Valvuloplasty Market - Volume and Forecast to 2031 (Units) - by Product Type
  • Table 17. Appendix: Balloon Aortic Valvuloplasty Market

List Of Figures

  • Figure 1. Europe Balloon Aortic Valvuloplasty Market Segmentation, by Country
  • Figure 2. Europe Balloon Aortic Valvuloplasty Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Europe Balloon Aortic Valvuloplasty Market Revenue (US$ Thousand), 2021-2031
  • Figure 5. Market Positioning Analysis, 2023
  • Figure 6. Europe Balloon Aortic Valvuloplasty Market Share (%) - by Product Type (2023 and 2031)
  • Figure 7. Non Compliant Balloons: Europe Balloon Aortic Valvuloplasty Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 8. Semi Compliant Balloons: Europe Balloon Aortic Valvuloplasty Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 9. Europe: Balloon Aortic Valvuloplasty Market by Key Countries - Revenue 2023 (US$ Thousand)
  • Figure 10. Europe Balloon Aortic Valvuloplasty Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 11. Germany: Europe Balloon Aortic Valvuloplasty Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 12. United Kingdom: Europe Balloon Aortic Valvuloplasty Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 13. France: Europe Balloon Aortic Valvuloplasty Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 14. Italy: Europe Balloon Aortic Valvuloplasty Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 15. Spain: Europe Balloon Aortic Valvuloplasty Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 16. Rest of Europe Balloon Aortic Valvuloplasty Market - Revenue and Forecast to 2031(US$ Thousand)